Severe Asthma Treatment Market Charts Course Towards US$ 36.18 Billion Valuation by 2033

According to Future Market Insights, the worldwide severe asthma therapies market share is anticipated to expand at a 5.1% CAGR from 2023 to 2033, reaching US$ 36.18 billion. Millions of patients worldwide who suffer from severe asthma now have hope thanks to the discovery of personalised medicines and biologics that have revolutionised the way the illness is managed.

Biologics, which are made from living organisms, have emerged as a promising development in the treatment of severe asthma by targeting specific immune system pathways that cause inflammation in the airways. In clinical trials, these medications shown remarkable efficacy and are increasingly being used to treat severe asthma patients who do not respond well to standard therapy.

Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16760

Some of the most commonly used biologics for severe asthma treatment are omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. These medications have been found to improve lung function, reduce asthma exacerbations, and improve overall quality of life in severe asthma patients when administered subcutaneously or intravenously.

The global Severe Asthma Treatment market is predicted to develop in the future years as more people are diagnosed with severe asthma and more breakthrough medications become available.

Key Takeaways:

The market for Severe Asthma Treatment is expected to increase at a 5.1% CAGR between 2023 and 2033.
In 2023, it is expected that the inhaled route of administration would account for 40% of the severe asthma therapy market.
North America is expected to retain 45% of the market for severe asthma therapy in 2023.
Europe’s market for Severe Asthma Treatment is expected to account for 39% of the total by 2023.

“Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst

Competitive Landscape

Key players in the Severe Asthma Treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion

GlaxoSmithKline’s discovery and marketing of a biologic drug called Nucala has been one of the company’s most significant breakthroughs in the treatment of severe asthma (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody that is used to treat severe eosinophilic asthma, which is characterised by high eosinophil levels in the blood and airways.
Novartis’ most major contribution to the treatment of severe asthma (omalizumab) has been the development and commercialization of a biologic medication called Xolair. Xolair is a monoclonal anti-IgE antibody that is used to treat severe allergic asthma caused by allergens such as pollen, dust mites, and animal dander.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Severe Asthma Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

Key Segments:

Drug Class: